\n
Pre-Screening, Collection, and Safety<\/h3>\n
$\"\"$ <\/p>\n<\/div>\n
$\"\"$ <\/p>\n
<\/p>\n
Wharton’s Jelly is a minimally manipulated flowable human allograft developed from eligible human umbilical cord tissue. It contains the highest therapeutics quality bioactive biomolecules of Wharton\u2019s Jelly-derived stem cells and its extracellular matrix. These molecules are found to exhibit immunomodulatory properties and recruit native stem cells to initiate healing and regeneration of damaged tissue. Our proprietary method ensures the highest quality of our product and preserves its therapeutic value.<\/span><\/p>\n
MSK<\/span><\/strong>\u00a0Physiotherapy aims to help you improve and manage problems that affect muscles, joints and soft tissues like ligaments and tendons.<\/span><\/p>\n
Available sizes: 2cc | 1cc | .5cc<\/span><\/p>\n
(Contact for Doctor Pricing 972-800-6670- ***Bulk orders and discounts available***)<\/span><\/span><\/em><\/span><\/p>\n
<\/p>\n
Wharton’s Derived from?<\/h3>\n
Wharton’s jelly cells are derived from the inner jelly substance in the umbilical cord from a healthy cesarian delivery. (Full Pre Screened to meet very stringent guidelines). Wharton’s jelly cells are isolated from a single donor. These cells have characteristics of MSCs and are widely investigated for their use in therapeutic applications. These cells enable researchers to investigate stem cell properties, regenerative medicine, and tissue engineering. In addition, they may be used for developmental studies.
\nDevelopment period: Postnatal<\/p>\n
<\/p>\n
Review Article<\/div>\n
Wharton\u2019s Jelly Derived Mesenchymal Stem Cells: Future of Regenerative Medicine? Recent Findings and Clinical Significance<\/h2>\n
^{1<\/sup>Department of Histology and Embryology, Center for Biostructure Research, Medical University of Warsaw
\n^{2<\/sup>Centre for Preclinical Research and Technology
\n^{3<\/sup>Polish Stem Cell Bank, Grzybowska<\/p>\n}}}
Abstract<\/h3>\n
\n
The Wharton’s jelly of the umbilical cord contains mucoid connective tissue and fibroblast-like cells. Using flow cytometric analysis, we found that mesenchymal cells isolated from the umbilical cord express matrix receptors (CD44, CD105) and integrin markers (CD29, CD51) but not hematopoietic lineage markers (CD34, CD45). Interestingly, these cells also express significant amounts of mesenchymal stem cell markers (SH2, SH3). We therefore investigated the potential of these cells to differentiate into cardiomyocytes by treating them with 5-azacytidine or by culturing them in cardiomyocyte-conditioned medium and found that both sets of conditions resulted in the expression of cardiomyocyte markers, namely N-cadherin and cardiac troponin I. We also showed that these cells have multilineage potential and that, under suitable culture conditions, are able to differentiate into cells of the adipogenic and osteogenic lineages. These findings may have a significant impact on studies of early human cardiac differentiation, functional genomics, pharmacological testing, cell therapy, and tissue engineering by helping to eliminate worrying ethical and technical issues.<\/p>\n
\n
Order Wharton's Jelly<\/a> or Call 972-800-6670<\/strong><\/pre>\n<\/div>\n<\/div>\n
New Doctor Account Set-up and Authorization<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"
Wharton’s Jelly<\/h1>\n
Looking for a doctor?
\nRequest Consultation<\/center><\/p>\n
\n
<\/div>\n
<\/div>\n
<\/div>\n
<\/div>\n